宁泌泰胶囊治疗Ⅲ型前列腺炎疗效研究

Efficacy of Ningmitai Capsule for Type Ⅲ Prostatitis

目的:评价宁泌泰胶囊治疗Ⅲ型前列腺炎的疗效和安全性。方法:采用宁泌泰胶囊自身对照的临床研究方法,共45例Ⅲ型前列腺炎患者入选,受试者口服宁泌泰胶囊,4粒/次,3次/d,4周为1疗程。以NIH-CPSI评分为主要疗效指标,评价宁泌泰胶囊治疗效果;用不良事件及检测治疗前后患者尿常规及肝肾功能指标评估其安全性。结果:NIH-CPSI总分治疗前为(19.31±2.18),治疗4周后下降为(12.53±6.22)(P<0.01);疼痛症状评分治疗前为(8.46±2.18),治疗2周后为(5.92±3.04)(P<0.05),治疗4周后下降为(4.45±3.90)(P<0.01)。总有效率为73%。结论:宁泌泰胶囊能明显降低Ⅲ型前列腺炎患者的NIH-CPSI评分,具有较好的疗效和临床安全性,为后期大规模临床研究奠定了良好的基础。

Objecfive To evaluate the clinical efficacy and safety of Ningmitai Capsule in the treatment of type III prostatitis.Methods This multi-centered self-control clinical trial included 45 males with type III prostatitis.The subjects were treated with Ningmitai Capsule at the dose of 4 capsules 1 time,three times a day for 4 weeks.NIH-CPSI score,as the main therapeutic index was examined.The laboratory results of urine routine examinations and liver and kidney function tests were used for evaluating the safety based on the adverse events.Results NIH-CPSI total score was(19.31±2.18)before treatment and(12.53±6.22)after 4 weeks of treatment(P<0.01).The scores of pain symptom after 2 weeks and 4 weeks of treatment were(5.92±3.04)and(4.45±3.90),both decreased than that before the treatment(8.46±2.18,P<0.05).The total efficiency was 73%.Conclusion Ningmitai Capsule is effective in the treatment of type III prostatitis with no obvious adverse events.